immunocore-logo-2018
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
August 01, 2022 07:00 ET | Immunocore Holdings Limited
Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022 Oral presentation...
BLI Logo Aug 2021.jpg
Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo
April 29, 2022 12:30 ET | Berkeley Lights, Inc
EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18th Annual PEGS Boston...
TCR UK establishes marketing partnership with SEO agency Woya Digital
April 14, 2022 10:43 ET | Woya Digital
Birmingham, UK, April 14, 2022 (GLOBE NEWSWIRE) -- In a move that will improve online visibility and increase audience numbers for the TCR UK Championship, a partnership has been secured with...
LogoPressRelease.jpg
Fluidigm Announces First Multimodal Single-Cell Application for the C1
July 10, 2018 08:30 ET | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation, a leader in mass cytometry and microfluidics technologies, today announced a new bimodal single‑cell application...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
December 05, 2016 07:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Therapy in Multiple Myeloma
October 27, 2016 10:05 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10
October 18, 2016 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Provides Update on Clinical Study Evaluating its SPEAR® T-Cell Therapy Targeting NY-ESO-1 in Ovarian Cancer
October 12, 2016 09:15 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Oct. 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that its amended...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
July 26, 2016 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
June 20, 2016 09:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European...